Scarica l'app Stockscreener
3.30
2.08%
-0.07
Precedente Chiudi:
$3.37
Aprire:
$3.35
Volume 24 ore:
245.58K
Relative Volume:
0.58
Capitalizzazione di mercato:
$207.46M
Reddito:
$12.14M
Utile/perdita netta:
$-99.50M
Rapporto P/E:
-2.4378
EPS:
-1.3537
Flusso di cassa netto:
$-56.37M
1 W Prestazione:
+2.17%
1M Prestazione:
+47.98%
6M Prestazione:
+192.04%
1 anno Prestazione:
+366.83%
Intervallo 1D:
$3.095
$3.4522
Intervallo di 1 settimana:
$2.99
$4.00
Portata 52W:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
3.30 | 207.46M | 12.14M | -99.50M | -56.37M | -1.3537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com
Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat
Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus
Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada
Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - Sahm
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates - AlphaStreet
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics 2025 10-K: Revenue $12.14M, EPS (1.29) - TradingView
Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
PRLD: Secured $60M upfront from Incyte, boosting cash and extending runway into Q2 2027 - TradingView
Prelude Therapeutics (PRLD) Advances Key Drug Programs with IND Clearance - GuruFocus
Prelude Therapeutics Earnings Report: Q4 Overview - Benzinga
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - Yahoo Finance
Aug Analyst Calls: Can Prelude Therapeutics Incorporated outperform under higher oil prices2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Prelude Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Volume Report: Is Prelude Therapeutics Incorporated a cyclical or defensive stockQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday - MarketBeat
PRLD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Wrap: Is Prelude Therapeutics Incorporated backed by strong institutional buyingMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Quarterly Risk: Does Prelude Therapeutics Incorporated have consistent dividend growthJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Guidance Update: Is Prelude Therapeutics Incorporated stock trending bullishTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is Prelude Therapeutics Incorporated a cyclical or defensive stock2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru
Is Prelude Therapeutics Incorporated in a long term uptrendJuly 2025 Market Mood & Technical Buy Zone Confirmation - mfd.ru
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9%Should You Sell? - MarketBeat
Is Prelude Therapeutics Incorporated stock trending bullishWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Prelude Therapeutics Secures FDA Clearance for Key Drug Candidate - AD HOC NEWS
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Take Profit: Does Prelude Therapeutics Incorporated have a sustainable dividendTrade Analysis Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Did PRLD Stock Surge 13% Today? - Stocktwits
Aug Wrap: Is ETRACS 2xMonthly Pay Leveraged Index ETN benefiting from interest rate changes2025 Market WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Why did PRLD stock surge 13% today? - MSN
Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance - BioWorld MedTech
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens - Investing.com Canada
FDA clears Prelude Therapeutics’ IND for JAK2 inhibitor in blood disorders - Investing.com Canada
Prelude Therapeutics (PRLD) Advances Blood Cancer Drug Trial wit - GuruFocus
Prelude Therapeutics Incorporated Receives FDA Clearance of Investigational New Drug Application for PRT12396 - marketscreener.com
Prelude Therapeutics stock surges after FDA clears IND for cancer drug By Investing.com - Investing.com South Africa
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
Prelude Therapeutics stock surges after FDA clears IND for cancer drug - Investing.com India
Prelude Therapeutics receives FDA clearance of investigational new drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor - marketscreener.com
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):